Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

75.10USD
27 Mar 2017
Change (% chg)

$0.73 (+0.98%)
Prev Close
$74.37
Open
$74.81
Day's High
$75.31
Day's Low
$74.79
Volume
462,383
Avg. Vol
638,728
52-wk High
$83.58
52-wk Low
$66.93

NVS.N

Chart for NVS.N

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $195,095.91
Shares Outstanding(Mil.): 2,627.11
Dividend: 2.75
Yield (%): 3.69

Financials

  NVS.N Industry Sector
P/E (TTM): 26.58 29.17 29.94
EPS (TTM): 2.80 -- --
ROI: 6.21 13.48 13.01
ROE: 8.84 14.39 14.16

Novartis heart drug portfolio hit by failed serelaxin study

ZURICH Novartis's heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.

Mar 22 2017

UPDATE 2-Novartis heart drug portfolio hit by failed serelaxin study

* Analysts say failure puts added pressure on Entresto franchise

Mar 22 2017

Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance

ZURICH Novartis has won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer's Ibrance.

Mar 14 2017

Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance

ZURICH Novartis has won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer's Ibrance.

Mar 14 2017

UPDATE 1-Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance

* Consensus forecasts point to sales of $1.5 bln by 2022 (Adds analyst comment, Novartis response, Astex Pharma role)

Mar 14 2017

Novartis wins FDA approval for breast cancer drug aiming for Pfizer's Ibrance

ZURICH, March 13 Novartis on Monday won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women with a difficult-to-treat form of breast cancer, challenging Pfizer's fast-growing Ibrance.

Mar 13 2017

FDA approves Novartis drug as first-line treatment for breast cancer

Novartis AG said on Monday that the U.S. Food and Drug Administration had approved the company's experimental drug, kisqali, as a first-line treatment for a type of breast cancer in postmenopausal women, in combination with another breast cancer drug.

Mar 13 2017

FDA approves Novartis drug as first-line treatment for breast cancer

March 13 Novartis AG said on Monday that the U.S. Food and Drug Administration had approved the company's experimental drug, kisqali, as a first-line treatment for a type of breast cancer in postmenopausal women, in combination with another breast cancer drug.

Mar 13 2017

Swiss stocks - Factors to watch on March 6

ZURICH, March 6 The Swiss blue-chip SMI was seen opening virtually unchanged at 8669 points on Monday, according to premarket indications by bank Julius Baer .

Mar 06 2017

Swiss stocks - Factors to watch on March 2

ZURICH, March 2 The Swiss blue-chip SMI was seen opening 0.1 percent firmer at 8,645 points on Thursday, according to premarket indications by bank Julius Baer .

Mar 02 2017

More From Around the Web

Competitors

Earnings vs. Estimates